company background image
D6M logo

genedrive DB:D6M Stock Report

Last Price

€0.022

Market Cap

€15.9m

7D

12.8%

1Y

-80.0%

Updated

29 Dec, 2024

Data

Company Financials

D6M Stock Overview

Engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. More details

D6M fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

genedrive plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for genedrive
Historical stock prices
Current Share PriceUK£0.022
52 Week HighUK£0.11
52 Week LowUK£0.002
Beta-0.10
1 Month Change91.30%
3 Month Change193.33%
1 Year Change-80.00%
3 Year Change-95.11%
5 Year Changen/a
Change since IPO-98.72%

Recent News & Updates

Recent updates

Shareholder Returns

D6MDE Life SciencesDE Market
7D12.8%1.4%0.5%
1Y-80.0%-4.5%7.2%

Return vs Industry: D6M underperformed the German Life Sciences industry which returned -4.5% over the past year.

Return vs Market: D6M underperformed the German Market which returned 7.2% over the past year.

Price Volatility

Is D6M's price volatile compared to industry and market?
D6M volatility
D6M Average Weekly Movement155.2%
Life Sciences Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: D6M's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: D6M's weekly volatility has increased from 93% to 155% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200043Gino Mielewww.genedriveplc.com

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides c system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.

genedrive plc Fundamentals Summary

How do genedrive's earnings and revenue compare to its market cap?
D6M fundamental statistics
Market cap€15.89m
Earnings (TTM)-€8.54m
Revenue (TTM)€604.50k

26.3x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
D6M income statement (TTM)
RevenueUK£501.00k
Cost of RevenueUK£4.18m
Gross Profit-UK£3.67m
Other ExpensesUK£3.40m
Earnings-UK£7.07m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.013
Gross Margin-733.33%
Net Profit Margin-1,412.18%
Debt/Equity Ratio0%

How did D6M perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 17:27
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

genedrive plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark BrewerCavendish
Vadim Alexandre KhalilDaniel Stewart & Company
John SavinEdison Investment Research